Chronic Granulomatous Disease

1. Disease Information

Overview. Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency (inborn error of immunity) caused by defects in the phagocyte NADPH oxidase complex (NOX2 system). Because neutrophils, monocytes, macrophages, and eosinophils cannot mount a normal respiratory burst — the burst of superoxide and downstream reactive oxygen species (ROS) that kills ingested microbes — patients suffer recurrent, life-threatening bacterial and fungal infections and a paradoxical tendency to granuloma formation and hyperinflammation (e.g., inflammatory bowel disease–like colitis). It is the prototypical defect of phagocyte killing (IUIS classification: "congenital defects of phagocyte number or function").

Think of the neutrophil as a cell that swallows a bacterium and is supposed to detonate a tiny oxidative bomb inside the phagosome. In CGD the fuse is cut — the microbe is engulfed but survives, and the frustrated immune system walls it off in a granuloma instead.

Key identifiers: - MONDO: MONDO:0018305 (chronic granulomatous disease, umbrella); X-linked form MONDO:0010071 - OMIM (phenotype series): - 306400 — CGD, X-linked (CYBB / gp91-phox) - 233690 — CGD, autosomal recessive, cytochrome b–negative (CYBA / p22-phox) - 233700 — CGD, autosomal recessive, cytochrome b–positive, type I (NCF1 / p47-phox) - 233710 — CGD, autosomal recessive, type II (NCF2 / p67-phox) - 613960 — CGD, autosomal recessive, type III (NCF4 / p40-phox) - 618935 — CGD due to CYBC1/EROS deficiency - Orphanet: ORPHA:379 - ICD-10: D71 (Functional disorders of polymorphonuclear neutrophils); ICD-11: 4A00.10 - MeSH: D006105 ("Granulomatous Disease, Chronic")

Synonyms / historical names: CGD; chronic granulomatous disease of childhood; congenital dysphagocytosis; "fatal granulomatosis of childhood" (historical, pre-antibiotic era); Bridges–Good syndrome; progressive septic granulomatosis; NADPH oxidase deficiency.

Data derivation. The knowledge base entry should be an aggregated disease-level synthesis (OMIM, Orphanet, GeneReviews, national/international CGD registries), not individual-EHR-derived. Major aggregate cohorts include the U.S. national registry of 368 patients (PMID 10844935, Winkelstein et al., Medicine 2000), the European experience (van den Berg et al., PLoS One 2009, PMID 19381301), and the residual-oxidase survival cohort of 287 patients (PMID 21190454, Kuhns et al., NEJM 2010).

Recent comprehensive reviews suitable as backbone citations: Roos D, Br Med Bull 2016; Arnold DE & Heimall JR, "A Review of Chronic Granulomatous Disease," Adv Ther 2017 (PMID ~29168050, verify); Yu JE et al., "Considerations in the Diagnosis of CGD," J Pediatric Infect Dis Soc 2018 (PMID 29746674); and the Justiz Vaillant/StatPearls chapter (PMID via NBK493171).

2. Etiology

Primary cause — genetic. CGD is monogenic. It results from loss-of-function variants in any one of six genes encoding subunits of the phagocyte NADPH oxidase (NOX2) complex or its assembly chaperone:

"Molecular defects in any of these five genes (CYBB for gp91phox … CYBA for p22phox, NCF1 for p47phox, NCF2 for p67phox, and NCF4 for p40phox) can occur in 90% of patients" — supported by GeneReviews and the MDPI review (verify exact wording against PMID before use).

CYBB is X-linked; the other five are autosomal recessive. In Western/outbred populations X-linked disease predominates (males ~80% of patients); in populations with high consanguinity, autosomal recessive forms rise to parity or majority.

Environmental/infectious triggers. No environmental exposure causes CGD, but infections are the clinical trigger. Catalase-positive organisms are the pathogenic linchpin (see §5). Live vaccines (notably BCG) can cause disseminated disease ("BCGosis") in undiagnosed infants.

Risk factors. - Genetic risk: hemizygous CYBB variant in males; biallelic pathogenic variants in an AR gene; carrier mother of an X-linked proband. Family history is the dominant risk factor. - Consanguinity markedly increases AR-form risk. - Sex: male (X-linked predominance). - No established modifiable lifestyle risk factors.

Protective factors. In a well-documented gene–environment/genotype–phenotype effect, residual NADPH oxidase activity is strongly protective: patients retaining measurable superoxide production have markedly better survival (PMID 21190454, Kuhns et al.). Certain "leaky" CYBB missense/splice variants (e.g., the X91⁻ and X91ᵛᵃʳⁱᵃᵇˡᵉ subtypes) confer milder disease. X-linked carrier females with skewed X-inactivation toward the wild-type allele (>10–20% oxidase-normal neutrophils) are usually clinically protected from infection, though they may develop lupus-like/photosensitive and inflammatory features.

Gene–environment interactions. The central interaction is genotype (residual ROS) × microbial exposure: the lower the residual oxidase, the more catalase-positive organisms establish infection. There is no classic toxicant GxE; the "environment" is the microbiome/pathogen load.

3. Phenotypes

CGD phenotypes fall into two arms: (A) infectious and (B) inflammatory/granulomatous. Onset is usually infancy to early childhood (most diagnosed at 1–3 years; milder AR/p47-phox cases may present in adolescence/adulthood). Course is chronic-lifelong, episodic/recurrent. Severity is variable, tracking residual oxidase activity.

A. Infectious phenotypes

• Recurrent bacterial and fungal infections — the defining feature. Suggested HP: Recurrent bacterial infections (HP:0002718), Recurrent fungal infections (HP:0002841 — verify), Immunodeficiency (HP:0002721).
• Pneumonia / recurrent pneumonia, often Aspergillus — HP:0002090 (Pneumonia); Aspergillosis HP:0033100 (verify). Frequency: very frequent (leading cause of infection and death).
• Suppurative/lymphadenitis and abscesses — lymphadenitis (HP:0002716 — verify), liver abscess (staphylococcal, characteristically "dense/caseous") — Hepatic abscess (verify ID), perianal/perirectal abscess, skin abscesses/pustular dermatitis.
• Osteomyelitis (including Serratia, Aspergillus, Burkholderia) — HP:0002754 (verify).
• Septicemia / sepsis (Burkholderia, Salmonella) — Sepsis (verify).
• Otitis, sinusitis, gingivitis/stomatitis, aphthous ulcers.

B. Inflammatory/granulomatous phenotypes

• Granuloma formation — hallmark; obstructing granulomas of GU (bladder) and GI tract. Suggested HP: Granuloma (HP:0032252 — verify).
• Inflammatory bowel disease (IBD)–like colitis — up to ~40–50% of patients, especially X-linked; diarrhea, failure to thrive, perianal disease, strictures. HP: Colitis (HP:0002583 — verify), Diarrhea (HP:0002014), Inflammatory abnormality of the large intestine.

  "…up to 50% of patients having gastrointestinal involvement meeting diagnostic criteria for inflammatory bowel disease" (USIDNET registry, PMID 35.../PMC9086117 — verify).

• Gastric outlet obstruction / antral narrowing, esophageal/ureteral strictures.
• Hepatosplenomegaly and lymphadenopathy — Splenomegaly (HP:0001744), Hepatomegaly (HP:0002240), Lymphadenopathy (verify).
• Failure to thrive / growth delay / short stature — HP:0001508 (Failure to thrive), HP:0001510 (Growth delay).
• Chorioretinitis / retinal lesions; discoid-lupus/photosensitive skin lesions (especially in X-linked carriers).
• Autoimmune/autoinflammatory features (lupus-like, JIA-like, antiphospholipid).

Laboratory-abnormality phenotypes

• Abnormal/absent neutrophil respiratory burst (DHR-123 flow cytometry, NBT) — the central lab phenotype.
• Anemia of chronic disease, leukocytosis, elevated ESR/CRP, hypergammaglobulinemia, elevated IL-18/IFN-γ in inflamed tissue (PMC6813411).

Quality-of-life impact. Chronic infections, IBD-like colitis, frequent hospitalizations, prolonged IV antimicrobials, growth failure, and (historically) shortened lifespan substantially reduce QoL; colitis is a major driver of morbidity. Formal EQ-5D/SF-36 CGD datasets are sparse — flag as data-limited.

4. Genetic / Molecular Information

Causal genes & products (HGNC): - CYBB (hgnc:2578) → gp91-phox / NOX2 (catalytic β-subunit of flavocytochrome b₅₅₈). - CYBA (hgnc:2577) → p22-phox (α-subunit; stabilizes gp91-phox in the membrane). - NCF1 (hgnc:7660) → p47-phox ("organizer" cytosolic factor). - NCF2 (hgnc:7661) → p67-phox ("activator" cytosolic factor; binds Rac). - NCF4 (hgnc:7662) → p40-phox (cytosolic; phagosomal targeting via PX domain). - CYBC1 / EROS (verify HGNC) → chaperone required for gp91-phox/p22-phox expression.

Use lowercase hgnc: CURIEs per repo convention.

Variant landscape. - CYBB: highly heterogeneous — nonsense, frameshift, splice-site, missense, large deletions/insertions across the gene. Classified by residual protein/function: X91⁰ (absent gp91-phox, no oxidase — most severe), X91⁻ (reduced), X91⁺ (normal protein, non-functional). Large contiguous Xp21 deletions can produce a contiguous gene syndrome (CGD + McLeod/Kell phenotype ± Duchenne muscular dystrophy ± retinitis pigmentosa/ornithine transcarbamylase). - NCF1: the ΔGT dinucleotide deletion (c.75_76delGT) at the start of exon 2 accounts for the vast majority of p47-phox alleles; it arises from recombination with adjacent NCF1 pseudogenes (ψNCF1), complicating molecular diagnosis and gnomAD frequency estimates. - Variant classification (ACMG/AMP): most are pathogenic/likely pathogenic loss-of-function; consult ClinVar and the curated CYBB/NCF1 mutation databases (Roos et al.). Somatic vs germline: germline (X-linked hemizygous or AR biallelic); no somatic mechanism. - Functional consequence: loss of function (failure to assemble/activate the oxidase). A few missense variants are hypomorphic (partial function → milder phenotype). A distinct p40-phox (NCF4) defect selectively impairs intracellular/phagosomal ROS with relatively preserved extracellular burst, giving a colitis-predominant, infection-mild phenotype.

Modifier genes / genetic modifiers. Residual oxidase level is the dominant severity modifier (functionally, not a separate locus). Polymorphisms in myeloperoxidase, mannose-binding lectin, FcγR, and inflammatory loci have been proposed to modify infection/inflammation risk (weaker evidence). X-inactivation skewing modifies carrier-female phenotype.

Epigenetic information. No established primary epigenetic mechanism; X-linked carrier phenotype is governed by X-chromosome inactivation (lyonization) patterns. Flag as not-a-major-feature.

Chromosomal abnormalities. Large Xp21 contiguous deletions (structural) as above; detectable by MLPA/CMA/karyotype. Otherwise CGD is a single-gene disorder.

Allele frequency. Individual pathogenic variants are rare; because CGD is severe, causal alleles are at very low frequency in gnomAD. The NCF1 ΔGT is confounded by pseudogene mapping — treat gnomAD NCF1 frequencies with caution.

5. Environmental Information

Infectious agents (central to CGD). The classic vulnerability is to catalase-positive organisms (catalase degrades microbial H₂O₂ that could otherwise substitute for the missing host oxidant). The "big five" CGD pathogens: 1. Staphylococcus aureus (catalase⁺; liver abscess, lymphadenitis, osteomyelitis) — NCBITaxon:1280 2. Burkholderia (Pseudomonas) cepacia complex (pneumonia, sepsis — high mortality) — NCBITaxon:87882/292 3. Serratia marcescens (osteomyelitis, soft-tissue) — NCBITaxon:615 4. Nocardia species (necrotizing pneumonia) — NCBITaxon:1817 5. Aspergillus species (A. fumigatus, A. nidulans — the latter almost pathognomonic; invasive pulmonary/osteo aspergillosis; leading cause of death) — NCBITaxon:746128 (A. fumigatus)

Other important agents: Salmonella, Granulibacter bethesdensis, Chromobacterium violaceum, Mycobacterium (including BCG vaccine strain and M. tuberculosis), Candida spp.

"Aspergillus species was the first cause of infection and of death in cohorts, which underscores the importance of antifungal prophylaxis with itraconazole." (review; verify).

Environmental/lifestyle factors. Exposure to decaying organic matter/mulch/gardening (mold — Aspergillus, and mulch pneumonitis, an acute fulminant fungal alveolitis after heavy inhalation) is a recognized precipitant. Live vaccines (BCG, live Salmonella typhi) are contraindicated. Smoking/aerosolized fungal exposure worsens pulmonary risk. No dietary cause.

6. Mechanism / Pathophysiology

Core molecular defect. The phagocyte NADPH oxidase (NOX2 complex) normally assembles at the phagosomal/plasma membrane: the membrane flavocytochrome b₅₅₈ (gp91-phox + p22-phox) docks the cytosolic regulatory factors p47-phox, p67-phox, p40-phox and the small GTPase Rac2 (Rac1 in some cells). Assembly enables electron transfer from cytosolic NADPH across the membrane to molecular O₂, generating superoxide (O₂•⁻) — the respiratory (oxidative) burst. Superoxide dismutates to H₂O₂ and, with myeloperoxidase, forms hypochlorous acid and other microbicidal ROS.

Suggested GO terms: respiratory burst (GO:0045730), superoxide anion generation (GO:0042554), superoxide metabolic process (GO:0006801), superoxide-generating NAD(P)H oxidase activity (GO:0016175, MF), defense response to fungus (GO:0050832), phagocytosis (GO:0006909), inflammatory response (GO:0006954).

Causal chain (upstream → downstream): 1. Loss-of-function variant in a NOX2-complex gene → failure to assemble/activate NADPH oxidase (upstream trigger). 2. Absent/deficient respiratory burst → failure to generate O₂•⁻/H₂O₂/HOCl in the phagosome. 3. Impaired oxygen-dependent microbial killing → ingested catalase-positive organisms survive intracellularly (catalase-negative organisms self-supply H₂O₂ and are still killed). 4. Recurrent/persistent infection by the characteristic pathogens → abscesses, pneumonia, osteomyelitis, sepsis. 5. Failure to clear organisms/antigen + defective apoptosis/efferocytosis and dysregulated inflammation → persistent macrophage activation → granuloma formation and sterile hyperinflammation (colitis, obstructive granulomas). This is the paradox: too little killing and too much inflammation.

Why the hyperinflammation? (downstream mechanisms). ROS are not only microbicidal — they are anti-inflammatory signals. In their absence: - Defective NLRP3 inflammasome regulation and excess IL-1β / IL-18 (redox normally restrains inflammasome activity). - Impaired neutrophil apoptosis and macrophage efferocytosis → prolonged inflammatory cell persistence. - Defective autophagy/LC3-associated phagocytosis → failure to degrade cargo, sustained NF-κB and inflammasome signaling. - Reduced tryptophan→kynurenine (IDO) and impaired Nrf2 signaling, failure to inactivate pro-inflammatory mediators, and defective neutrophil extracellular trap (NET) formation (ROS-dependent NETosis is deficient). - Impaired resolution of inflammation and dysregulated Th17/IL-17 responses.

Backbone reviews for the inflammation mechanism: "Chronic granulomatous disease: why an inflammatory disease?" (PMC4230281); "Hyperinflammation in CGD and anti-inflammatory role of the phagocyte NADPH oxidase," Segal et al., Semin Immunopathol 2008; high tissue IL-18/IFN-γ (PMC6813411). Verify PMIDs.

Cell types (CL): neutrophil (CL:0000775), monocyte (CL:0000576), macrophage (CL:0000235), eosinophil (CL:0000771), granulocyte/myeloid leukocyte (CL:0000094 / CL:0000766).

Tissue-damage mechanisms: granulomatous/obstructive tissue remodeling, abscess/necrosis from uncontrolled infection, fibrosis (bladder/GI strictures), and inflammatory tissue injury from sustained cytokine output.

Molecular profiling. Transcriptomic/proteomic studies show heightened inflammatory-gene and inflammasome signatures in CGD phagocytes; single-cell and functional (CRISPR) work on NOX2 assembly exists but is not central to the clinical entry — flag as supplementary. Diagnostic "profiling" is functional (DHR flow), not omics.

7. Anatomical Structures Affected

Organ level (primary): - Lung (UBERON:0002048) — pneumonia, invasive aspergillosis, mulch pneumonitis, fibrosis. - Lymph nodes (UBERON:0000029) — suppurative lymphadenitis. - Liver (UBERON:0002107) — hepatic abscess (often staphylococcal), hepatomegaly, nodular regenerative hyperplasia/portal hypertension. - Spleen (UBERON:0002106) — splenomegaly, abscess. - Skin/soft tissue (UBERON:0002097) — abscesses, pustular/eczematoid dermatitis, granulomatous lesions. - Gastrointestinal tract — colon (UBERON:0001155) and small intestine (UBERON:0002108): IBD-like colitis, granulomas, strictures; stomach/gastric antrum (outlet obstruction). - Bone — osteomyelitis (small bones, ribs, vertebrae). - Genitourinary tract — bladder granulomas, ureteral obstruction. - Bone marrow (UBERON:0002371) — site of the defective myeloid progenitors and target of curative HSCT/gene therapy. - Eye — chorioretinal lesions.

Body systems: immune/hematopoietic (primary), respiratory, digestive, integumentary, musculoskeletal, genitourinary, hepatobiliary.

Cell/tissue level: myeloid phagocytes (neutrophils, monocytes/macrophages, eosinophils); granuloma = epithelioid macrophages ± multinucleated giant cells and lymphocytes; characteristic pigment-laden (lipofuscin) macrophages on histology.

Subcellular level (GO cellular component): phagocytic vesicle / phagosome membrane (GO:0045335), plasma membrane / specific (secondary) granule membrane, and the NADPH oxidase complex (GO:0043020, NADPH oxidase complex) localized to phagosome and plasma membrane. Flavocytochrome b₅₅₈ resides in secretory vesicles/specific granule and plasma membranes.

Localization/lateralization: multifocal and bilateral/systemic — infections and granulomas occur wherever phagocytes confront organisms; no consistent lateralization.

8. Temporal Development

Onset. Typically infancy/early childhood — most X-linked patients present and are diagnosed within the first 1–3 years of life; AR forms (especially p47-phox) skew later, with some diagnosed in adolescence or adulthood. Onset pattern is chronic with acute infectious exacerbations superimposed.

Progression. Chronic, lifelong, punctuated by recurrent infections and inflammatory flares (episodic/relapsing). Without curative therapy, cumulative organ damage (pulmonary fibrosis, GI strictures, hepatic disease) accrues. Inflammatory complications (colitis) often persist or worsen independent of infection control.

Stages / natural history: no formal staging. Historically, mortality was highest in the first decade; modern prophylaxis has shifted major morbidity/mortality into adolescence and adulthood, where Aspergillus and Burkholderia infections and progressive inflammatory/GI disease dominate.

Critical windows: infancy (BCG avoidance; early diagnosis prevents catastrophic first infections); pre-adolescence is the recommended window for HSCT in severe (low-residual-oxidase) patients while organ damage is limited (PMID 21190454 rationale). Remission of infections is treatment-induced (prophylaxis, curative HSCT/gene therapy); spontaneous remission does not occur.

9. Inheritance and Population

Epidemiology. - Incidence/prevalence: ~1 in 200,000–250,000 live births in the U.S. (Winkelstein registry, PMID 10844935); worldwide estimates ~1/100,000–1/250,000 depending on consanguinity. Approx. 20 new U.S. cases/year historically.

"A registry of United States residents with CGD was established in 1993 … 368 patients were registered; 259 had the X-linked recessive form … and 81 had one of the autosomal recessive forms." (PMID 10844935). - Sex ratio: ~80% male (X-linked predominance) in outbred populations. - Age distribution: diagnosis concentrated in early childhood; survival now often into 4th–5th decades and beyond.

Inheritance genetics. - Pattern: X-linked recessive (CYBB) + autosomal recessive (CYBA, NCF1, NCF2, NCF4, CYBC1). - Penetrance: essentially complete in affected males (X-linked) and biallelic AR individuals; expressivity is variable (residual-oxidase-dependent). - Carrier females (X-linked): mosaic neutrophil populations; usually asymptomatic for infection but may have discoid-lupus/photosensitive and autoimmune features; risk of symptomatic infection rises when wild-type neutrophils fall below ~10–20%. - Consanguinity: raises AR-form frequency; in high-consanguinity regions AR forms equal or exceed X-linked. - Founder effects: NCF1 ΔGT (pseudogene-mediated) is a recurrent, quasi-"founder" allele; regional founder variants reported (e.g., specific NCF2/CYBA alleles in Middle Eastern and Israeli Arab/Jewish populations). - Germline mosaicism / anticipation: not a feature (no repeat expansion). New (de novo) CYBB variants occur in a minority of X-linked cases. - Carrier frequency: low; population-specific for AR alleles.

Geographic distribution. Worldwide; relative gene-form distribution varies with consanguinity. No endemic clustering beyond that driven by founder alleles.

10. Diagnostics

Functional screening/confirmation (the core test): - Dihydrorhodamine-123 (DHR) flow cytometry — current gold-standard functional assay; measures the neutrophil oxidative burst after PMA stimulation. Quantifies residual oxidase and reveals the bimodal pattern of X-linked carriers. (LOINC-codable oxidative-burst assay — verify LOINC.) - Nitroblue tetrazolium (NBT) slide test — older qualitative assay, largely superseded by DHR. - Both detect the defining lab abnormality: absent/reduced respiratory burst.

Confirmatory protein/biochemical tests: immunoblot/flow for gp91-phox and p22-phox (cytochrome b₅₅₈ "positive/negative" typing); cytochrome b spectral assay; NADPH oxidase activity assays.

Genetic testing (definitive subtype/carrier assignment): - Targeted single-gene sequencing guided by DHR pattern + protein typing (e.g., CYBB in males with X-linked pattern). - CGD/primary-immunodeficiency NGS gene panels or WES/WGS when the pattern is ambiguous. WGS/CMA/MLPA needed for large deletions/contiguous Xp21 syndromes and to resolve NCF1 pseudogene complexity (NCF1 requires specialized assays — gene-specific PCR/pyrosequencing for the ΔGT and pseudogene ratio). - Carrier testing / prenatal diagnosis available once the familial variant is known.

Imaging & supportive tests: CT chest (pneumonia, fungal nodules, "halo" sign of aspergillosis), abdominal imaging/CT for liver abscess and bowel disease, endoscopy/biopsy for colitis. Histopathology: non-caseating granulomas, pigmented lipofuscin-laden macrophages, abscesses (SNOMED/pathology-codable).

Differential diagnosis: other phagocyte disorders (leukocyte adhesion deficiency, myeloperoxidase deficiency, Chédiak–Higashi, glucose-6-phosphate dehydrogenase deficiency with severe deficit — can mimic oxidase failure), hyper-IgE syndrome, Mendelian susceptibility to mycobacterial disease, Crohn disease (for the colitis phenotype), and other IEIs with granulomas. Key distinguisher: the abnormal DHR/NBT respiratory-burst assay.

Screening: not part of standard newborn screening (TREC-based SCID screening does not detect CGD). Cascade/carrier screening of at-risk relatives once a proband variant is identified is standard.

11. Outcome / Prognosis

Survival / mortality. - Prognosis has improved dramatically. Historically fatal in childhood; with modern prophylaxis, many patients survive into the 4th–5th decade. Contemporary mortality is ~1.5–3% per year in registry cohorts. - X-linked disease carries worse prognosis than AR (lower residual oxidase), and residual oxidase strongly predicts survival — patients in the lowest superoxide quartile have the highest mortality, with divergence after age ~20 (PMID 21190454, Kuhns et al.).

"…patients with the least residual … reactive oxygen intermediate production had the lowest survival." (Kuhns 2010 — verify exact wording). - Leading causes of death: invasive fungal (Aspergillus) infection and Burkholderia sepsis/pneumonia.

Morbidity / complications. Recurrent pneumonia and pulmonary fibrosis, hepatic abscess and portal hypertension/nodular regenerative hyperplasia, IBD-like colitis (major morbidity), GU/GI obstructive granulomas, growth failure, and inflammatory/autoimmune disease. Frequent hospitalizations and long antimicrobial courses.

Curative-therapy outcomes. Allogeneic HSCT now yields ~90% overall survival in modern series (matched-sibling and matched-unrelated donors), with best results in younger patients with matched donors and controlled infection at transplant. - 712-patient international HSCT study (Chiesa et al., Blood 2020, PMID ~32202630 — verify): low graft failure and mortality across ages. - Single-center late-survival cohort: OS ~90% at 2 years and ~81% at 5 years (JACI 2022). - Reduced-intensity conditioning HSCT: Güngör et al., Lancet 2014 (PMID 24161820) — 2-year survival ~96% in a prospective series.

Prognostic factors: residual oxidase activity (dominant), genotype/inheritance (X-linked worse), age and organ damage at HSCT, donor match, active infection at transplant, severity of inflammatory/GI disease.

12. Treatment

A. Lifelong prophylaxis (standard of care)

• Antibacterial: trimethoprim–sulfamethoxazole (co-trimoxazole) (CHEBI: trimethoprim 45924; sulfamethoxazole 9332) — reduces bacterial infections. MAXO: antibiotic therapy / pharmacotherapy (verify MAXO ID).
• Antifungal: itraconazole (CHEBI:6076) — landmark placebo-controlled prophylaxis trial (Gallin et al., NEJM 2003, PMID 12802026 — verify) significantly reduced serious fungal infections; posaconazole (CHEBI:64355)/voriconazole (CHEBI:10023) used for treatment/breakthrough.

  "Itraconazole … was effective in preventing fungal infections in patients with chronic granulomatous disease." (NEJMoa021931 — verify).

• Immunomodulatory: Interferon-γ (IFN-γ, 1b) three-times-weekly SC — the International CGD Cooperative Study (NEJM 1991, PMID 1846940 — verify) showed ~70% reduction in serious infections.

  "…interferon gamma reduced the frequency of serious infections in patients with chronic granulomatous disease." (verify exact quote).

B. Acute infection management

Aggressive, culture-directed IV antibacterials/antifungals; often prolonged courses. Granulocyte transfusions for severe refractory infection (adjunct). Surgical drainage of abscesses.

C. Management of inflammatory/granulomatous disease

Corticosteroids for obstructive granulomas and colitis; steroid-sparing agents; anti-inflammatory/immunosuppressive therapy for IBD-like colitis. Caution: anti-TNF biologics increase severe infection risk in CGD (case reports of fatal fungal infection) — use judiciously.

D. Curative therapy

• Allogeneic hematopoietic stem cell transplantation (HSCT) — the established cure; replaces defective myeloid lineage. MAXO: hematopoietic stem cell transplantation (verify MAXO ID; MAXO:0010039 organ transplantation is too generic). Reduced-intensity conditioning improves outcomes (Güngör 2014).
• Autologous ex vivo lentiviral gene therapy (X-linked/gp91-phox) — corrects CD34⁺ HSPCs with a myeloid-specific promoter-driven gp91-phox vector.

  Kohn DB et al., Nat Med 2020 (PMID 31988463): nine X-CGD patients treated; "…six of the seven surviving patients demonstrated stable vector copy numbers (0.4–1.8 copies per neutrophil)" and stable oxidase-positive neutrophils sufficient for clinical benefit (verify exact wording). Modality: GENE_THERAPY; earlier retroviral trials were complicated by insertional myelodysplasia/clonal expansion, motivating self-inactivating lentiviral designs.

• Investigational: gene-corrected p47-phox lentiviral vectors (preclinical, PMC8575060); CRISPR/base-editing approaches (preclinical).

Pharmacogenomics: azole levels vary widely (CYP3A4/itraconazole absorption); therapeutic drug monitoring recommended. No specific germline PGx gating beyond the disease genotype.

Supportive care: avoidance of mulch/decaying vegetation and live vaccines; dental/skin hygiene; nutritional support for colitis-related growth failure; genetic counseling.

13. Prevention

• Primary prevention: the disease itself cannot be prevented (monogenic), but infection prevention is central — lifelong co-trimoxazole + itraconazole ± IFN-γ; avoidance of environmental mold exposure and contraindication of live vaccines (BCG, oral typhoid).
• Secondary prevention: early diagnosis via family history and DHR testing of at-risk newborns; prompt cascade/carrier screening.
• Tertiary prevention: aggressive early treatment of infections; surveillance for colitis, liver, and pulmonary complications; timely referral for HSCT/gene therapy before irreversible organ damage.
• Genetic counseling & reproductive options: carrier testing, prenatal diagnosis, and preimplantation genetic diagnosis once the familial variant is known.
• Prophylaxis (medication): co-trimoxazole (antibacterial), itraconazole (antifungal), IFN-γ (immunomodulatory) — see §12.

14. Other Species / Natural Disease

• Taxonomy of affected species: primarily human (NCBITaxon:9606). Naturally occurring CGD-like NADPH-oxidase disease is documented in dogs (NCBITaxon:9615) and described in cattle.
• Natural animal disease / OMIA: canine CGD-type leukocyte oxidase defects and, notably, Bovine Leukocyte Adhesion Deficiency is a distinct phagocyte disorder (do not conflate); search OMIA for "granulomatous"/NADPH oxidase entries in dog/cattle for veterinary orthologs.
• Orthologous genes: CYBB/NCF1/NCF2/CYBA/NCF4 are conserved across mammals (mouse Cybb, Ncf1, Ncf2, Cyba, Ncf4 — NCBI Gene). Deep evolutionary conservation of the NOX2 phagocyte-oxidase system.
• Comparative biology: knockout mice recapitulate the killing defect and granuloma/hyperinflammation, validating the anti-inflammatory role of NOX2-derived ROS across species.
• Transmission: none — non-infectious, non-zoonotic (it is a germline genetic disorder).

15. Model Organisms

• Mouse (Mus musculus, NCBITaxon:10090) — primary model.
• Cybb (gp91-phox) knockout and Ncf1 (p47-phox) knockout mice are the workhorse models. They reproduce (a) defective respiratory burst and increased susceptibility to Aspergillus, Burkholderia, Staphylococcus, Salmonella, and (b) exaggerated/granulomatous inflammation and sterile hyperinflammation — directly demonstrating that NOX2-derived ROS restrain inflammation. Models: knockout, conditional, and humanized/gene-corrected lines used in gene-therapy preclinical work (MGI, IMSR).
• Used to model prophylaxis, HSCT, and lentiviral gene-therapy correction (e.g., p47-phox lentiviral rescue restoring anti-Salmonella function, Gene Ther 2020).
• Cellular/in vitro models: patient CD34⁺ HSPCs, iPSC-derived neutrophils/macrophages (for gene-editing/gene-therapy testing), immortalized myeloid lines (e.g., PLB-985 gp91-phox knockouts) — key IN_VITRO systems for oxidase-assembly studies and CRISPR correction.
• Model characteristics / limitations: mouse models recapitulate the killing defect and hyperinflammation well but differ in pathogen spectrum and colitis phenotype severity; the human NCF1 pseudogene architecture has no direct murine counterpart, limiting modeling of the common human p47-phox ΔGT allele. Flag as HUMAN_MODEL_MISMATCH candidates where mouse inflammation/colitis does not fully mirror human IBD-like disease.
• Resources: MGI (mouse), IMPC/KOMP (knockouts), Cellosaurus (PLB-985 and derivatives), Alliance of Genome Resources (orthology).

Suggested dismech Entry Scaffolding (quick reference)

• MONDO: MONDO:0018305 (umbrella); consider modeling X-linked (MONDO:0010071) and AR forms as subtypes (has_subtypes: X-linked / CYBB, AR p47-phox / NCF1, AR p67-phox / NCF2, AR p22-phox / CYBA, AR p40-phox / NCF4, AR CYBC1/EROS).
• Causal genes (hgnc): CYBB (hgnc:2578), CYBA (hgnc:2577), NCF1 (hgnc:7660), NCF2 (hgnc:7661), NCF4 (hgnc:7662), CYBC1 (verify).
• Core GO/CL/UBERON/CHEBI/MAXO terms as listed in §§6–7, 12 — all require OAK validation.
• Pathophysiology causal chain: NOX2-complex LoF variant → failed oxidase assembly → absent respiratory burst → impaired killing of catalase-positive microbes → recurrent infection and (parallel arm) impaired ROS-dependent inflammation control → granuloma/colitis/hyperinflammation.
• Priority evidence PMIDs to fetch & verify: 10844935 (registry/epidemiology), 21190454 (residual oxidase/survival), 12802026 (itraconazole prophylaxis — verify), 1846940 (IFN-γ trial — verify), 31988463 (lentiviral gene therapy), 24161820 (RIC-HSCT — verify), plus the Blood 2020 712-patient HSCT study and the USIDNET IBD/CGD paper (verify PMIDs).

Sources (web-verified during this research)

• GeneReviews: Chronic Granulomatous Disease (NBK99496)
• StatPearls: Chronic Granulomatous Disease (NBK493171)
• CGD: Epidemiology, Pathophysiology, and Genetic Basis (J Pediatric Infect Dis Soc, PMC5946813)
• Winkelstein et al. 2000, national registry of 368 patients (PMID 10844935)
• Kuhns et al. 2010, Residual NADPH Oxidase and Survival (NEJM; PMID 21190454)
• Kohn et al. 2020, Lentiviral gene therapy for X-linked CGD (Nat Med)
• Gallin et al., Itraconazole prophylaxis (NEJM)
• CGD: why an inflammatory disease? (PMC4230281)
• CGD with IBD — USIDNET Registry (PMC9086117)
• Hematopoietic cell transplantation in CGD: 712 children and adults (Blood 2020)
• Orphanet: Chronic granulomatous disease (ORPHA:379)
• CGD: Commonly Associated Pathogens, Diagnosis and Treatment (PMC10534792)
• MedlinePlus Genetics: Chronic granulomatous disease

Bottom line: CGD is a monogenic phagocyte NADPH-oxidase defect — the cell can swallow the bug but can't light the oxidative match — producing the twin signatures of recurrent catalase-positive infections and paradoxical granulomatous hyperinflammation. It's genetically well-mapped (six genes, X-linked CYBB dominant), functionally diagnosable (DHR flow), medically manageable (co-trimoxazole + itraconazole + IFN-γ), and increasingly curable (HSCT ~90% survival; lentiviral gene therapy maturing). Residual oxidase activity is the master dial for severity and survival. Remember: fetch and validate every PMID snippet and ontology ID before writing them into the YAML.